• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Broad Mucosal and Systemic Immunity in Mice Induced by Intranasal Booster With a Novel Recombinant Adenoviral Based Vaccine Protects A

tetano

Editor, Senior Moderator
J Med Virol


. 2025 Apr;97(4):e70326.
doi: 10.1002/jmv.70326. Broad Mucosal and Systemic Immunity in Mice Induced by Intranasal Booster With a Novel Recombinant Adenoviral Based Vaccine Protects Against Divergent Influenza A Virus

Jia Li[SUP] 1 [/SUP], Tangqi Wang[SUP] 1 2 [/SUP], Xiaojuan Guo[SUP] 2 [/SUP], Yujie Jiang[SUP] 1 [/SUP], Liye Jin[SUP] 3 [/SUP], Qiaohong Chu[SUP] 2 [/SUP], Xuchang Shan[SUP] 3 [/SUP], Lingfang Zhang[SUP] 4 [/SUP], Ruiwen Han[SUP] 1 2 [/SUP], Chengcheng Zhai[SUP] 2 [/SUP], Donghong Wang[SUP] 2 [/SUP], Yao Deng[SUP] 2 [/SUP], Baoying Huang[SUP] 2 [/SUP], Zhuozhuang Lu[SUP] 2 [/SUP], Wenjie Tan[SUP] 1 2 [/SUP]



Affiliations
Abstract

The development of broad-spectrum universal influenza vaccines and optimization of vaccination strategies to address the threats posed by pandemics and emerging influenza viruses are critical for public health. In this study, an adenovirus type 5 vector-based influenza vaccine carrying the hemagglutinin (HA) stem of H1, HA stem of H3, and neuraminidase (NA) of N1 from the influenza virus was constructed. Immune responses were evaluated in mice using various vaccination strategies: prime-only (intramuscular [IM] or intranasal [IN]) and prime-boost (IM + IN). Compared with the prime-only strategy, the prime-boost strategy significantly enhanced the systemic immune response, inducing higher levels of antigen-specific IgG, mucosal IgA, and T cell immunity in the spleen and lungs. Furthermore, the IN boosting strategy provided complete protection in mice challenged with the H1N1-PR8, rgH3N2-X31, and rgH5N1-Vietnam viruses, significantly reducing viral loads in the lungs and alleviating lung tissue pathologies. In conclusion, this study elucidates potential avenues for the development and application of universal influenza vaccines using customized mucosal boosting strategies.

Keywords: adenovirus vector‐based influenza vaccine; intranasal booster; mucosal immunity; systemic immunity; universal influenza vaccine.

 
Back
Top